
    
      Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound
      Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid
      Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR
      Pathway Activation
    
  